NEW YORK (GenomeWeb News) – Perlegen Sciences intends to release its first diagnostic product, which is focused on stratifying risk and diagnosing breast cancer, during the first half of 2009, CEO Bryan Walser said on Thursday at the UBS Global Life Sciences Conference here.
 
The panel will contain eight single nucleotide polymorphisms, five of which are exclusive to Perlegen. The firm believes that its panel will have utility in both risk stratification as well as helping to guide treatment selection after diagnosis.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.